Posts by Amanda C. Guidon, MD
Course and Outcomes of COVID-19 in Series of Patients with Myasthenia Gravis
A case series of five patients with pre-existing myasthenia gravis who were hospitalized for COVID-19 demonstrates the management challenges.
Review: COVID-19 and Neuromuscular Disorders
Little is known about neuromuscular complications of severe coronavirus infections, so Massachusetts General Hospital researchers say neurologists should stay alert during the COVID-19 pandemic.
Dr. Amanda Guidon is a neuromuscular neurologist at the Massachusetts General Hospital and an Assistant Professor of Neurology at Harvard Medical School. She graduated from Brown University and received her medical degree from the University of Rochester. She completed her internship, neurology residency and a two-year neuromuscular fellowship at Duke University Medical Center.
Dr. Guidon joined the MGH faculty in 2013. Her clinical practice is dedicated to patients with neuromuscular diseases, and particularly immune-mediated disorders such as myasthenia gravis and CIDP. She has an additional clinical and research interest in the neuromuscular complications of cancer and its therapies, particularly the neurologic immune related adverse events of cancer immunotherapies. She is the Director of the MGH Myasthenia Gravis Clinic, which is a MGFA-designated "MG Partners in Care" Center. Dr. Guidon is Program Director of the Partners Neuromuscular Medicine Fellowship.
Dr. Guidon participates in clinical trials in myasthenia and serves on the medical and scientific advisory board of the Myasthenia Gravis Foundation of America (MGFA). She is board certified in Neurology, Neuromuscular Medicine and Electrodiagnostic Medicine.